Section Arrow
EXEL.NASDAQ
- Exelixis
Quotes are at least 15-min delayed:2026/04/17 17:20 EDT
After Hours
Last
 44.89
0 (0.00%)
Bid
44.13
Ask
45.5
High 45.5 
Low 44.5 
Volume 190.54K 
Regular Hours (Closed)
Last
 44.89
+0.51 (+1.15%)
Day High 
45.4319 
Prev. Close
44.38 
1-M High
46.1 
Volume 
2.50M 
Bid
44.13
Ask
45.5
Day Low
44.62 
Open
45 
1-M Low
40.8375 
Market Cap 
11.27B 
Currency 美元 
P/E 15.97 
%Yield -- 
10-SMA 44.52 
20-SMA 43.31 
50-SMA 42.97 
52-W High 49.62 
52-W Low 33.755 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
2.78/4.00
Enterprise Value
11.45B
Balance Sheet
Book Value Per Share
8.51
Cash Flow
Cash Flow Yield
0.07
Income Statement
Total Revenue
10.50M
Operating Revenue Per Share
6.99
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TOVXTheriva Biologics Inc0.2572+0.0049+1.94%0.09PE
After Hours 0.4125 +0.1553 +60.38%
PBMPsyence Biomedical Ltd.7.6+1.73+29.47%-- 
After Hours 8.82 +1.22 +16.05%
GERNGeron Corp1.68-0.01-0.59%-- 
After Hours 1.69 +0.01 +0.60%
IBRXImmunityBio7.7+0.45+6.21%-- 
After Hours 7.73 +0.03 +0.39%
ADMAADMA Biologics11.01+0.27+2.51%17.92PE
After Hours 10.95 -0.06 -0.54%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.